EUVIMEDEUVIMED entdecken
Crossref

Treatment of hypopigmented burn hypertrophic scars with short‐term topical tacrolimus does not lead to repigmentation

Esteban A Molina iD, Taryn E Travis, Lou'ay Hussein, Mary A Oliver, John W Keyloun, Lauren T Moffatt, Jeffrey W Shupp, Bonnie C Carney iD

Lasers in Surgery and Medicine · 2024

DOI: 10.1002/lsm.23754 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lasers in Surgery and Medicine, 2024. Verfasst von Esteban A Molina und 7 weiteren Autor:innen. Beteiligte Einrichtung: Firefighters' Burn and Surgical Research Laboratory, MedStar Health Research Institute, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: Cicatrix, Hypertrophic, Vitiligo, Hypopigmentation, Burns. Die Arbeit nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Dyschromia is an understudied aspect of hypertrophic scar (HTS). The use of topical tacrolimus has successfully shown repigmentation in vitiligo patients through promotion of melanogenesis and melanocyte proliferation. It was hypothesized that HTSs treated with topical tacrolimus would have increased repigmentation compared to controls. Methodology Full‐thickness burns in red Duroc pigs were either treated with excision and meshed split‐thickness skin grafting or excision and no grafting, and these wounds formed hypopigmented HTSs ( n = 8). Half of the scars had 0.1% tacrolimus ointment applied to the scar twice a day for 21 days, while controls had no treatment. Further, each scar was bisected with half incurring fractional ablative CO 2 laser treatment before topical tacrolimus application to induce laser‐assisted drug delivery (LADD). Pigmentation was evaluated using a noninvasive probe to measure melanin index (MI) at Days 0 (pretreatment), 7, 14, and 21. At each timepoint, punch biopsies were obtained and fixed in formalin or were incubated in dispase. The formalin‐fixed biopsies were used to evaluate melanin levels by H&E staining. The biopsies incubated in dispase were used to obtain epidermal sheets. The ESs were then flash frozen and RNA was isolated from them and used in quantitative reverse transcription polymerase chain reaction for melanogenesis‐related genes: Tyrosinase (TYR), TYR‐related protein‐1 (TYRP1), and dopachrome tautomerase (DCT). Analysis of variance test with Šídák's multiple comparisons test was used to compare groups.

Results

Over time, within the grafted HTS and the NS group, there were no significant changes in MI, except for Week 3 in the −Tacro group. (+Tacro HTS= pre = 685.1 ± 42.0, w1 = 741.0 ± 54.16, w2 = 750.8 ± 59.0, w3 = 760.9 ± 49.8) (−Tacro HTS= pre = 700.4 ± 54.3, w1 = 722.3 ± 50.7, w2 = 739.6 ± 53.2, w3 = 722.7 ± 50.5). Over time, within the ungrafted HTS and the NS group, there were no significant changes in MI. (+Tacro HTS= pre = 644.9 ± 6.9, w1 = 661.6 ± 3.3, w2 = 650.3 ± 6.2, w3 = 636.3 ± 7.4) (−Tacro HTS= pre = 696.8 ± 8.0, w1 = 695.8 ± 12.3, w2 = 678.9 ± 14.0, w3 = 731.2 ± 50.3). LADD did not lead to any differential change in pigmentation compared to the non‐LADD group. There was no evidence of increased melanogenesis within the tissue punch biopsies at any timepoint. There were no changes in TYR, TYRP1, or DCT gene expression after treatment.

Conclusion

Hypopigmented HTSs treated with 0.1% tacrolimus ointment with or without LADD did not show significantly increased repigmentation. This study was limited by a shorter treatment interval than what is known to be required in vitiligo patients for repigmentation. The use of noninvasive, topical treatments to promote repigmentation are an appealing strategy to relieve morbidity associated with dyschromic burn scars and requires further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cicatrix, HypertrophicVitiligoHypopigmentationBurnsAnimalsHumansSwineTacrolimusOintmentsMelaninsHypertrophyFormaldehydeTreatment Outcome

Stichwörter der Autor:innen

dyschromiahypertrophic scarpigmentationtacrolimus

Substanzen

TacrolimusOintmentsMelaninsFormaldehyde

Autor:innen und Institutionen

  • Firefighters' Burn and Surgical Research Laboratory, MedStar Health Research Institute, Washington, District of Columbia, USA.
  • The Burn Center, MedStar Washington Hospital Center, Washington, District of Columbia, USA.
  • Department of Surgery, Georgetown University School of Medicine, Washington, District of Columbia, USA.
  • Department of Plastic and Reconstructive Surgery, Georgetown University School of Medicine, Washington, District of Columbia, USA.
  • Department of Biochemistry and Molecular Biology, Georgetown University School of Medicine, Washington, District of Columbia, USA.

ORCID-Profile: Esteban A Molina, Bonnie C Carney

Zitieren

APA

Molina, E. A., Travis, T. E., Hussein, L., Oliver, M. A., Keyloun, J. W., Moffatt, L. T., Shupp, J. W., & Carney, B. C. (2024). Treatment of hypopigmented burn hypertrophic scars with short‐term topical tacrolimus does not lead to repigmentation. Lasers in Surgery and Medicine. https://doi.org/10.1002/lsm.23754

Vancouver

Molina EA, Travis TE, Hussein L, Oliver MA, Keyloun JW, Moffatt LT, et al. Treatment of hypopigmented burn hypertrophic scars with short‐term topical tacrolimus does not lead to repigmentation. Lasers in Surgery and Medicine. 2024. doi:10.1002/lsm.23754

BibTeX
@article{Molina2024,
  author = {Molina, Esteban A and Travis, Taryn E and Hussein, Lou'ay and Oliver, Mary A and Keyloun, John W and Moffatt, Lauren T and Shupp, Jeffrey W and Carney, Bonnie C},
  title = {Treatment of hypopigmented burn hypertrophic scars with short‐term topical tacrolimus does not lead to repigmentation},
  journal = {Lasers in Surgery and Medicine},
  year = {2024},
  doi = {10.1002/lsm.23754}
}
Kostenlos starten →